Aurinia Pharmaceuticals: Comparative Analysis Reveals Voclosporin As A Drug With Mediocre Efficacy And Class-Typical Safety (NASDAQ:AUPH) | Seeking Alpha
Voclosporin for Lupus Nephritis — NephJC
Aurinia Demonstrates Voclosporin's Superiority over Standard-of-Care in Lupus Nephritis
Voclosporin for Lupus Nephritis — NephJC
2018 Is An Ideal Entry Point For Aurinia Pharmaceuticals (NASDAQ:AUPH) | Seeking Alpha
FDA Approves Aurinia Pharmaceuticals' LUPKYNIS™ (voclosporin) for Adult Patients
Aurinia And Voclosporin In Lupus Nephritis: The Countdown Begins (NASDAQ:AUPH) | Seeking Alpha
Voclosporin for Lupus Nephritis — NephJC
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet
Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study - ACR Meeting Abstracts
Lupus nephritis: high death rate for voclosporin in Phase III
voclosporin - Twitter Search / Twitter
VisualAbstract: Voclosporin shows clinical promise for treatment of active lupus nephritis | 2 Minute Medicine
FDA Approves Aurinia Pharmaceuticals' LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis | Business Wire
dough on Twitter: "$AUPH Positive Ph. III clinical trial results (2019) Approval and launch of voclosporin for the treatment of lupus nephritis (late 2020 – early 2021) Distribution partnerships for voclosporin in
Filing of Application for Lupus Nephritis Treatment Accepted by FDA | Lupus Foundation of America
LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis, US
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet
Aurinia Pharmaceuticals: R&D Day Update On Its Clinical Program And Pipeline Development (NASDAQ:AUPH) | Seeking Alpha
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet
Voclosporin: First Approval | SpringerLink
Aurinia And Voclosporin In Lupus Nephritis: The Countdown Begins (NASDAQ:AUPH) | Seeking Alpha
Don't Count Voclosporin Ophthalmic Solution Out (NASDAQ:AUPH) | Seeking Alpha
Safety data from clinical trials of voclosporin for plaque psoriasis | Download Table
